정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1150 | Recruiting | INvestigating TELmisartin Study | Covid19 | Drug: Telmisartan Oral Product Drug: Placebo |
Phase 2 | University of Hawaii, Queens Medical Center | OTHER | 40 | All | 18 Years | Queen's Medical Center, Honolulu, Hawaii, United States |
| 1149 | Recruiting | Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection | COVID-19 Pneumonia | Drug: Firazyr Other: SoC |
Phase 2 | Sebastian Videla | OTHER | 120 | All | 18 Years | Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Catalonia, Spain |
| 1148 | Not yet recruiting | Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. | Post COVID-19 Anosmia (Loss of Smell) | Drug: Aerosolized 13 cis retinoic acid plus Vitamin D Drug: Aerosolized All trans retinoic acid plus Vitamin D Other: Standard therapy |
Phase 4 | Kafrelsheikh University, Ministry of Health, Saudi Arabia, Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine , Jilin University China, Montefiore Health System and Albert Einstein College of Medicine, Newyork, United States of America (USA), Faculty of Science, Kafrelsheikh University, Egypt. | OTHER | 10000 | All | 18 Years ~ 70 Years | Quan Liu, Foshan, Guangdong, China Tamer Haydara, Kafr Ash Shaykh, Kafr Elshiekh, Egypt Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia |
| 1147 | Not yet recruiting | Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. | Covid19 Vaccine | Drug: Oral 13 cis retinoic acid Drug: Aerosolized 13 cis retinoic acid Combination Product: 13 cis retinoic acid doses orally in combination with spike protein based vaccine Combination Product: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine Biological: Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine |
Phase 2 | Kafrelsheikh University | OTHER | 360 | Male | 18 Years ~ 40 Years | |
| 1146 | Recruiting | Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19) | Endothelial Dysfunction | Biological: COVID-19 vaccine Biological: Concentrate beetroot Juice Biological: Nitrate-deplete beetroot juice |
Phase 1 | Queen Mary University of London | OTHER | 98 | All | 18 Years ~ 60 Years | The William Harvey Research Institute, London, United Kingdom |
| 1145 | Not yet recruiting | Investigation the Effect of Montelukast in COVID-19 | SARS-CoV-2 | Drug: Montelukast Oral Tablet Drug: Montelukast plus Favicovir (Favipiravir) Drug: Favicovir (Standard Treatment) |
Phase 2 | Bahce?ehir University, Medipol University, The Scientific and Technological Research Council of Turkey | OTHER | 380 | All | 18 Years | Bahcesehir University, School of Medicine, Department of Biophysics,, Istanbul, Turkey |
| 1144 | Completed | Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan | ARDS | Procedure: Therapeutic Plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: Mesenchymal stem cell therapy |
Not Applicable | UNICEF, Pak Emirates Military Hospital Rawalpindi | OTHER | 600 | All | 18 Years ~ 90 Years | Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan |
